TOPICA Announces Participation in BioPartnering North America

PALO ALTO, Calif., Jan. 25 /PRNewswire/ -- TOPICA Pharmaceuticals today announced that Greg Vontz, president and CEO, will present at BioPartnering North America on Monday, January 25, at 2:45 p.m. Pacific Time at the Westin Bayshore Resort in Vancouver, BC.

During the presentations, Mr. Vontz will provide an overview of TOPICA and its clinical development plans for luliconazole, one of the most potent and broad spectrum topical antifungal agents, for the treatment of onychomycosis (fungal infections of the nail) and tinea pedis (athlete's foot).

About TOPICA Pharmaceuticals

TOPICA is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing potent topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA is developing luliconazole for the treatment of tinea pedis (athlete's foot) and onychomycosis (fungal infections of the nail). For more information, please visit http://www.topicapharma.com.

SOURCE TOPICA Pharmaceuticals